Literature DB >> 3145164

Restless legs with antiepileptic drug therapy.

M E Drake1.   

Abstract

The restless legs syndrome is generally benign but is occasionally associated with anemia, metabolic disorder, or polyneuropathy. Leg restlessness with disruptive nocturnal myoclonus has been described as a sleep disorder. We report two patients with complex partial and secondarily generalized seizures, who developed restless legs while taking methsuximide and phenytoin. They had no evidence of metabolic disturbance or neuromuscular disease, although one patient had fragmented sleep and disruptive myoclonus on polysomnography, and leg restlessness subsided with change of antiepileptic drugs. These symptoms could reflect transient alteration in peripheral nerve function not evident by examination or electrophysiologic studies, sleep disturbance by antiepileptic drugs or the effects of temporal lobe seizure foci on perception of the physiologic state of nerves and muscles.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145164     DOI: 10.1016/s0303-8467(88)80037-4

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  4 in total

1.  Restless legs syndrome induced by topiramate: two more cases.

Authors:  Pedro Emilio Bermejo
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 2.  Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis.

Authors:  Romy Hoque; Andrew L Chesson
Journal:  J Clin Sleep Med       Date:  2010-02-15       Impact factor: 4.062

Review 3.  Restless legs and periodic leg movements in sleep syndromes.

Authors:  T C Wetter; T Pollmächer
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

Review 4.  Beyond tremor and rigidity: non-motor features of Parkinson's disease.

Authors:  Matthias Löhle; Alexander Storch; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2009-08-14       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.